EN
- Lactobacillus casei CCFM419
- Lactobacillus rhamnosus CCFM0528
- Bifidobacterium breve CCFM1217
- Lactobacillus gasseri CCFM1133
- Lactobacillus reuteri CCFM1145
- 1) Regulates Blood Glucose and Insulin Sensitivity
- 2) Reduces Cholesterol and Manages Body Weight
- 3) Lowers Uric Acid and Triglycerides
- 4) Promotes Cardiovascular Health (Reduces TMA)
MetaAKK™ Dietary Metabolism - Boost Metabolis
Formulation
Functionality
Scientific Support
Pre-clinical paper
1) (CCFM419) Wang, G., et al. (2017). Lactobacillus casei CCFM419 attenuates type 2 diabetes via a gut microbiota dependent mechanism. Food & Function, 8(9), 3155-3164.
2) (CCFM0528) Chen, P., et al. (2014). Oral administration of Lactobacillus rhamnosus CCFM0528 improves glucose tolerance and cytokine secretion in high-fat-fed, streptozotocin-induced type 2 diabetic mice. Journal of Functional Foods, 10, 318-326.
Patent
1) (CCFM1145) Jiangnan University, A strain of Lactobacillus reuteri capable of intervening in metabolic syndrome and application. Chinese Invention Patent, Granted Publication Number CN112322527A.
2) (CCFM1217) Jiangnan University, Bifidobacterium breve CCFM1217 capable of simultaneously reducing plasma and cecal trimethylamine (TMA) and its application. Chinese Invention Patent, Granted Publication Number CN114381406A.
3) (CCFM1133) Jiangnan University, Lactobacillus gasseri capable of alleviating and treating hyperuricemia. US Patent Application US20240000871A1 / WO2022127845A1.